Pricing in the Post-MFN World: Why 2026 Access Planning Needs Earlier Payer Validation
- Jul 1
- 4 min read
Want the downloadable brief? Get the full Signal 1 PDF and webinar replay resources from our Access Inflection resource page.
Market access planning is entering a new cycle. Pricing pressure, evidence expectations, contracting strategy, and stakeholder engagement are becoming more connected, and manufacturers can no longer assume that yesterday’s launch playbook will hold up in 2026.
During eMAX Health Systems’ webinar, The Access Inflection: When the 2025 Playbook Stops Working, a live panel of senior payer and market access leaders discussed five signals reshaping access planning for pharmaceutical and biotech teams.
The first signal: pricing in the post-MFN world.
While there is still uncertainty around how MFN-related policy pressure may evolve, payer expectations are already shifting. For manufacturers, the risk is not simply pricing too high or too low. The bigger risk is making major pricing, evidence, and access decisions without validating how payer decision-makers are evaluating value now.
Pricing Strategy Can No Longer Stand Alone
For years, many launch and access strategies were built around familiar assumptions: the approved indication, the unmet need, the perceived level of innovation, the existing comparator landscape, and historical pricing precedent.
Those inputs still matter. But they may no longer be enough.
As pricing scrutiny increases, payers are looking more closely at whether a therapy’s clinical value, evidence package, and economic rationale support the price being proposed. A product may have a meaningful clinical story, but if that story does not translate into payer-relevant evidence, it may not support premium pricing or preferred access.
One webinar panelist put it directly:
“Just because I have an FDA indication doesn’t mean that you’re going to be able to charge whatever you want or a premium to what’s on the marketplace today.”
That distinction is critical for 2026 planning. FDA approval may establish that a product can come to market, but it does not automatically establish how payers will evaluate price, formulary position, utilization management, or contracting expectations.
Evidence May Come Before Price
When asked where pressure may show up first for 2026 and 2027 launches, one panelist pointed directly to the evidence package.
Payers are evaluating more than approval status. They are looking at unmet need, efficacy, safety, inappropriate use or potential for misuse, and net cost. For manufacturers, that means pricing strategy needs to be connected earlier to evidence planning.
The stronger the connection between clinical value, appropriate use, economic impact, and current standards of care, the stronger the access story becomes.
This is especially important in high-cost categories, rare disease, oncology, immunology, and other areas where unmet need may exist, but payer tolerance for unsupported premium pricing is narrowing.
Real-World Evidence Is Becoming More Important
The panel also discussed the growing role of real-world evidence in payer decision-making.
One medical director noted that payers are seeing more real-world evidence used to support new therapies and defend value against competitive pressure. That trend has important implications for manufacturers. It is no longer enough to think about evidence as a launch requirement only. Evidence planning needs to support the full access lifecycle, including payer engagement, formulary review, contracting, and post-launch value defense.
For access teams, the question becomes: are we generating the evidence payers need to see, or are we relying on the evidence we already have?
What Manufacturers Should Pressure-Test Now
The post-MFN pricing environment is still evolving, but manufacturers do not need to wait for every policy detail to become clear before pressure-testing their strategy.
Access teams should be asking:
Are our pricing assumptions aligned with current payer expectations?
Does our evidence package support the value story we want to tell?
Have we validated whether our clinical differentiation is meaningful to payers?
Do we understand how payers may compare our product to current and emerging alternatives?
Are we prepared to explain the economic rationale behind our access strategy?
Have we tested how contracting scenarios may be received before decisions are finalized?
These questions matter because payer expectations can shift faster than internal planning cycles. By the time a product reaches launch, many of the most important pricing and access assumptions may already be difficult to change.
Where MAVA® Fits
MAVA® was built to help pharmaceutical and biotech teams bring current stakeholder insight into high-stakes market access decisions.
Through rapid, confidential engagement with curated payer and healthcare decision-maker panels, MAVA helps Commercial, Medical, HEOR, Pricing, and Access teams pressure-test assumptions before market conditions shift.
For pricing and access planning, MAVA can help teams explore:
How payers may evaluate a proposed price or value story
Which evidence gaps could create access risk
Whether clinical differentiation is meaningful enough to support preferred positioning
How contracting and rebate scenarios may be received
What payer objections may emerge during formulary review
How current market dynamics may affect 2026 and 2027 planning
The goal is not simply to gather feedback. It is to bring payer perspective into strategy early enough to shape better decisions.
The Takeaway
Pricing strategy can no longer be developed in isolation. In the post-MFN world, pricing, evidence, contracting, and payer engagement need to move together.
Manufacturers that validate assumptions earlier will be better positioned to understand payer expectations, defend value, and adapt before market conditions change.
Explore the full Access Inflection series
